SCHEMBL30983545

SCHEMBL30983545

N#CC1(Oc2ncnc3c2nc(-c2ccc(OCCN4CCNCC4)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HTR6 P50406 8/20 0.38
▸ CNR1 P21554 1/20 0.37
▸ PDE2A O00408 1/20 0.36
▸ HTR1A P08908 2/20 0.36
▸ DRD2 P14416 2/20 0.36
▸ HTR2A P28223 2/20 0.36
▸ HTR7 P34969 2/20 0.36
▸ LTA4H P09960 2/20 0.35
▸ LMNA P02545 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ RET P07949 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ TLR7 Q9NYK1 1/20 0.32
▸ HRH4 Q9H3N8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30984097 0.94 PDE2A (0.40) KDM4EALDH1A1HTR6CNR1PDE2A
SCHEMBL30983378 0.90 HTR6 (0.41) KDM4EALDH1A1HTR6CNR1PDE2A
SCHEMBL30983516 0.88 PDE2A (0.40) KDM4EALDH1A1HTR6CNR1PDE2A
SCHEMBL30983922 0.86 CNR1 (0.39) CNR1MAPK1RET
SCHEMBL30983385 0.85 KDM4E (0.42) KDM4EALDH1A1HTR6CNR1PDE2A
SCHEMBL30983434 0.85 PDE2A (0.39) KDM4EALDH1A1CNR1PDE2ALTA4H
SCHEMBL30983795 0.84 PDE2A (0.42) KDM4EALDH1A1HTR6PDE2ADRD2
SCHEMBL30984056 0.83 PDE2A (0.42) KDM4EALDH1A1HTR6PDE2ADRD2
SCHEMBL30984054 0.83 PDE2A (0.42) KDM4EALDH1A1HTR6PDE2ADRD2
SCHEMBL30983609 0.83 PDE2A (0.42) KDM4EALDH1A1HTR6PDE2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB KDM4E 2215/4885ALDH1A1 3824/4885HTR6 4806/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB KDM4E 2215/4885ALDH1A1 3824/4885HTR6 4806/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB KDM4E 2215/4885ALDH1A1 3824/4885HTR6 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback